Paper Details

  1. Home
  2. Paper Details

Combined Hydroxyurea and Verapamil in the Clinical Treatment of Refractory Meningioma: Human and Orthotopic Xenograft Studies.

Author: BarthTalmadge, BurtLindsay, DunsonWilliam, GillespieDavid L, HoangNguyen, JensenRandy L, KarsyMichael

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Overview

Previous in vitro and in vivo results suggested that hydroxyurea (HU) and verapamil could suppress meningioma growth. This study evaluated the clinical efficacy and safety of this approach for the treatment of refractory recurrent/progressive meningiomas.
Paper Details　
Original Abstract of the Article :
Previous in vitro and in vivo results suggested that hydroxyurea (HU) and verapamil could suppress meningioma growth individually and synergistically. We evaluated the clinical efficacy and safety of this approach for the treatment of refractory recurrent/progressive meningiomas and expanded our stu...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.wneu.2015.09.060

データ提供：米国国立医学図書館（NLM）

A New Approach to Meningioma Treatment: A Synergistic Duo

Meningioma, a type of brain tumor, is a tough nut to crack. It's like a stubborn sand dune, resistant to conventional treatments. This study investigates a potential new strategy for tackling refractory meningiomas, a combination of hydroxyurea (HU) and verapamil.

The authors explored the effectiveness of this drug combination both in clinical settings and in a xenograft orthotopic mouse model. The research suggests that HU and verapamil may work synergistically to suppress meningioma growth, potentially offering a new weapon in the fight against this challenging tumor.

A New Oasis in the Desert of Meningioma Treatment: Hope for Refractory Cases

This study offers a glimmer of hope for patients with refractory meningiomas. The synergistic combination of HU and verapamil may provide a new avenue for treatment, potentially improving outcomes for individuals facing this difficult diagnosis.

Finding a Path Through the Sand Dunes of Meningioma: Exploring New Treatment Options

The discovery of this potential synergistic effect of HU and verapamil opens up new pathways for treating refractory meningiomas. Further research is needed to fully explore its efficacy and safety, but this finding offers a beacon of hope for those navigating the complex landscape of brain tumor treatment.

Dr. Camel's Conclusion

This research takes a bold step forward in the treatment of refractory meningiomas. By combining the power of HU and verapamil, this study presents a potentially effective new approach for tackling this challenging tumor. As a researcher, I am excited about the potential impact of this discovery on improving outcomes for patients with refractory meningiomas.

Date :
  1. Date Completed 2016-06-29
  2. Date Revised 2016-02-09
Further Info :

Pubmed ID

26428319

DOI: Digital Object Identifier

10.1016/j.wneu.2015.09.060

Related Literature

Article Analysis
・Side Effects of trandolapril and verapamil
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.